These data indicate that surgery improves the condition of patients with moderate or intense globus pattern symptoms, but may make symptoms appear in asymptomatic of weakly symptomatic patients.

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

A Florida federal judge has issued a report and recommended that a sales representative pay more than $19 million to resolve ...

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December ...

a clinical series of patients operated for thyroid disease were assessed to measure the prevalence and severity of globus symptoms, before and three months after surgery. The survey was done at ...